MX2017008161A - Pirazolpiridinaminas. - Google Patents
Pirazolpiridinaminas.Info
- Publication number
- MX2017008161A MX2017008161A MX2017008161A MX2017008161A MX2017008161A MX 2017008161 A MX2017008161 A MX 2017008161A MX 2017008161 A MX2017008161 A MX 2017008161A MX 2017008161 A MX2017008161 A MX 2017008161A MX 2017008161 A MX2017008161 A MX 2017008161A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- pyrazolopyridinamines
- mknk1
- mknk2
- inhibitors
- Prior art date
Links
- MJEPPEQNLZSPAP-UHFFFAOYSA-N 1h-pyrazolo[4,3-b]pyridin-3-amine Chemical class C1=CN=C2C(N)=NNC2=C1 MJEPPEQNLZSPAP-UHFFFAOYSA-N 0.000 title abstract 2
- 101150115334 Mknk1 gene Proteins 0.000 title 1
- 101150058727 Mknk2 gene Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 206010065390 Inflammatory pain Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Compuestos de pirazolpiridinamina sustituida de fórmula general (I) según se los describe y define aquí, métodos para preparar dichos compuestos, compuestos intermediarios útiles para preparar dichos compuestos, composiciones farmacéuticas y combinaciones que comprenden a dichos compuestos y el uso de dichos compuestos para elaborar una composición farmacéutica para el tratamiento o la profilaxis de una enfermedad, en particular de un trastorno hiperproliferativo y/o de angiogénesis, como único agente o en combinación con otros ingredientes activos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14199096 | 2014-12-19 | ||
| EP15187501 | 2015-09-29 | ||
| PCT/EP2015/079587 WO2016096721A1 (en) | 2014-12-19 | 2015-12-14 | Pyrazolopyridinamines as mknk1 and mknk2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017008161A true MX2017008161A (es) | 2017-09-18 |
Family
ID=54884024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017008161A MX2017008161A (es) | 2014-12-19 | 2015-12-14 | Pirazolpiridinaminas. |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US10487092B2 (es) |
| EP (1) | EP3233866B1 (es) |
| JP (1) | JP2018501250A (es) |
| KR (1) | KR20170095985A (es) |
| CN (1) | CN107250138A (es) |
| AU (1) | AU2015366417A1 (es) |
| BR (1) | BR112017013148A2 (es) |
| CA (1) | CA2971242A1 (es) |
| CL (1) | CL2017001615A1 (es) |
| CO (1) | CO2017005968A2 (es) |
| CR (1) | CR20170264A (es) |
| CU (1) | CU20170086A7 (es) |
| DO (1) | DOP2017000146A (es) |
| EA (1) | EA201791363A1 (es) |
| EC (1) | ECSP17038893A (es) |
| GT (1) | GT201700138A (es) |
| IL (1) | IL252686A0 (es) |
| MX (1) | MX2017008161A (es) |
| NI (1) | NI201700078A (es) |
| PE (1) | PE20171104A1 (es) |
| PH (1) | PH12017501133A1 (es) |
| SG (1) | SG11201704916TA (es) |
| SV (1) | SV2017005466A (es) |
| TN (1) | TN2017000258A1 (es) |
| TW (1) | TW201625648A (es) |
| UY (1) | UY36460A (es) |
| WO (1) | WO2016096721A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI713455B (zh) * | 2014-06-25 | 2020-12-21 | 美商伊凡克特治療公司 | ＭｎＫ抑制劑及其相關方法 |
| WO2017081003A1 (en) * | 2015-11-12 | 2017-05-18 | Bayer Pharma Aktiengesellschaft | Substituted pyrazolopyridinamines |
| PE20191349A1 (es) | 2017-02-14 | 2019-09-30 | Effector Therapeutics Inc | Inhibidores de mnk sustituidos con piperidina y metodos relacionados con los mismos |
| CA3117169A1 (en) | 2018-10-24 | 2020-04-30 | Effector Therapeutics, Inc. | Crystalline forms of mnk inhibitors |
| CN111803476A (zh) * | 2020-08-14 | 2020-10-23 | 华中科技大学协和深圳医院 | 芬戈莫德用于抑制革兰阳性细菌活性的用途 |
| IL301285A (en) | 2020-09-10 | 2023-05-01 | Precirix N V | Antibody fragment against fap |
| US20230000986A1 (en) * | 2021-07-01 | 2023-01-05 | Board Of Regents, The University Of Texas System | Mnk inhibitors and eif4e phosphorylation modulation to treat inflammatory pain in the aged |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| CA3251753A1 (en) | 2022-05-02 | 2023-11-09 | Precirix N.V. | PRE-TARGETTING |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| JP4712702B2 (ja) * | 2003-07-24 | 2011-06-29 | バイエル・シエリング・フアーマ・アクチエンゲゼルシヤフト | 高増殖性疾患を処置するために有用な置換されたテトラヒドロベンゾチエノピリミジンアミン化合物 |
| US8207172B2 (en) | 2004-08-20 | 2012-06-26 | Bayer Intellectual Property Gmbh | Pyrimidinothienoindazoles useful for the treatment of hyperproliferative disorders |
| US8703941B2 (en) * | 2011-01-10 | 2014-04-22 | Nimbus Iris, Inc. | IRAK inhibitors and uses thereof |
| ES2591129T3 (es) * | 2012-05-21 | 2016-11-25 | Bayer Pharma Aktiengesellschaft | Tienopirimidinas |
| JP6235001B2 (ja) * | 2012-05-21 | 2017-11-22 | バイエル・ファルマ・アクティエンゲゼルシャフト | 置換ベンゾチエノピリミジン |
| EP2922840B1 (en) * | 2012-11-08 | 2016-12-21 | Bristol-Myers Squibb Company | Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators |
| WO2014118229A1 (en) * | 2013-02-01 | 2014-08-07 | Bayer Pharma Aktiengesellschaft | Substituted thienopyrimidines and pharmaceutical use thereof |
-
2015
- 2015-12-14 PE PE2017001100A patent/PE20171104A1/es not_active Application Discontinuation
- 2015-12-14 SG SG11201704916TA patent/SG11201704916TA/en unknown
- 2015-12-14 WO PCT/EP2015/079587 patent/WO2016096721A1/en not_active Ceased
- 2015-12-14 EA EA201791363A patent/EA201791363A1/ru unknown
- 2015-12-14 US US15/537,694 patent/US10487092B2/en active Active
- 2015-12-14 BR BR112017013148-0A patent/BR112017013148A2/pt not_active IP Right Cessation
- 2015-12-14 TN TN2017000258A patent/TN2017000258A1/en unknown
- 2015-12-14 CA CA2971242A patent/CA2971242A1/en active Pending
- 2015-12-14 MX MX2017008161A patent/MX2017008161A/es unknown
- 2015-12-14 CR CR20170264A patent/CR20170264A/es unknown
- 2015-12-14 AU AU2015366417A patent/AU2015366417A1/en not_active Abandoned
- 2015-12-14 JP JP2017533275A patent/JP2018501250A/ja active Pending
- 2015-12-14 KR KR1020177019615A patent/KR20170095985A/ko not_active Withdrawn
- 2015-12-14 EP EP15813014.6A patent/EP3233866B1/en active Active
- 2015-12-14 CN CN201580076266.7A patent/CN107250138A/zh active Pending
- 2015-12-14 CU CUP2017000086A patent/CU20170086A7/es unknown
- 2015-12-18 TW TW104142845A patent/TW201625648A/zh unknown
- 2015-12-18 UY UY0001036460A patent/UY36460A/es not_active Application Discontinuation
-
2017
- 2017-06-05 IL IL252686A patent/IL252686A0/en unknown
- 2017-06-16 PH PH12017501133A patent/PH12017501133A1/en unknown
- 2017-06-16 CO CONC2017/0005968A patent/CO2017005968A2/es unknown
- 2017-06-19 NI NI201700078A patent/NI201700078A/es unknown
- 2017-06-19 SV SV2017005466A patent/SV2017005466A/es unknown
- 2017-06-19 DO DO2017000146A patent/DOP2017000146A/es unknown
- 2017-06-19 CL CL2017001615A patent/CL2017001615A1/es unknown
- 2017-06-19 GT GT201700138A patent/GT201700138A/es unknown
- 2017-06-20 EC ECIEPI201738893A patent/ECSP17038893A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170095985A (ko) | 2017-08-23 |
| CU20170086A7 (es) | 2017-11-07 |
| SG11201704916TA (en) | 2017-07-28 |
| BR112017013148A2 (pt) | 2019-11-19 |
| NI201700078A (es) | 2017-09-22 |
| TN2017000258A1 (en) | 2018-10-19 |
| WO2016096721A1 (en) | 2016-06-23 |
| SV2017005466A (es) | 2018-10-02 |
| EP3233866A1 (en) | 2017-10-25 |
| EA201791363A1 (ru) | 2018-01-31 |
| PE20171104A1 (es) | 2017-08-07 |
| US10487092B2 (en) | 2019-11-26 |
| TW201625648A (zh) | 2016-07-16 |
| CO2017005968A2 (es) | 2017-10-20 |
| UY36460A (es) | 2016-07-29 |
| EP3233866B1 (en) | 2021-04-21 |
| IL252686A0 (en) | 2017-08-31 |
| CL2017001615A1 (es) | 2018-03-16 |
| CN107250138A (zh) | 2017-10-13 |
| CA2971242A1 (en) | 2016-06-23 |
| DOP2017000146A (es) | 2017-07-31 |
| AU2015366417A1 (en) | 2017-06-29 |
| JP2018501250A (ja) | 2018-01-18 |
| GT201700138A (es) | 2018-12-06 |
| ECSP17038893A (es) | 2017-07-31 |
| CR20170264A (es) | 2017-07-21 |
| US20180162877A1 (en) | 2018-06-14 |
| PH12017501133A1 (en) | 2017-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021550792A1 (en) | 2-(morpholin-4-yl)-1,7-naphthyridines | |
| PH12016501807A1 (en) | Novel compounds | |
| TN2017000258A1 (en) | Pyrazolopyridinamines as mknk1 and mknk2 inhibitors | |
| PH12017501079A1 (en) | 1,3-thiazol-2-yl substituted benzamides | |
| PH12016501581A1 (en) | Benzimidazol-2-amines as midh1 inhibitors | |
| PH12013500454A1 (en) | Substituted imidazopyridazines | |
| TN2015000371A1 (en) | Substituted imidazopyridazines | |
| MY168413A (en) | Amino-substituted imidazopyridazines | |
| PH12016500054A1 (en) | Substituted pyrazolo-pyridinamines | |
| PH12016500931A1 (en) | Thienopyrimidines as mknk1 and mknk2 inhibitors | |
| PH12016501932A1 (en) | Amido-substituted azole compounds | |
| PH12016501814A1 (en) | Inhibitors of the wnt signalling pathways | |
| UY36983A (es) | Pirazolopiridinaminas sustituidas | |
| MA39762A (fr) | Nouveaux composés | |
| TN2014000091A1 (en) | Amino-substituted imidazopyridazines | |
| UY37032A (es) | Compuestos de heteroarilbenzimidazol |